☆ 4.8 Meeting Abstract

TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).

CANCER RESEARCH (2010)

期刊

CANCER RESEARCH

卷 70, 期 -, 页码 -

出版社

AMER ASSOC CANCER RESEARCH

DOI: 10.1158/0008-5472.SABCS10-S1-6

关键词

-

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Oncology

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer

Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre

Summary: This study investigated the effect of adding everolimus to adjuvant therapy in early breast cancer and found that among high-risk patients, adding everolimus to adjuvant endocrine therapy did not improve disease-free survival. Tolerability was also a concern, with more than half of the patients discontinuing everolimus treatment before the study completion.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial

Takuji Iwase, Shigehira Saji, Kotaro Iijima, Kenji Higaki, Shoichiro Ohtani, Yasuyuki Sato, Yasuo Hozumi, Yoshie Hasegawa, Yasuhiro Yanagita, Hiroyuki Takei, Maki Tanaka, Hideji Masuoka, Masahiko Tanabe, Chiyomi Egawa, Yoshifumi Komoike, Toshitaka Nakamura, Hiroshi Ohtsu, Hirofumi Mukai

Summary: This study investigated the effects of extending the treatment with an aromatase inhibitor for 10 years on disease-free survival in postmenopausal hormone receptor-positive breast cancer patients. The results showed that extending the treatment with an aromatase inhibitor for an additional 5 years improved disease-free survival.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial

Manuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, Anita Giobbie-Hurder, Bent Ejlertsen, Vernon J. Harvey, Patrick Neven, Istvan Lang, Herve Bonnefoi, Andrew Wardley, Barbara Ruepp, Monica Castiglione, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Marco Colleoni, Beat Thurlimann, Meredith M. Regan

Summary: This study investigates cardiovascular events in breast cancer patients during treatment with different drugs and found that monotherapy with letrozole is associated with a higher risk of ischemic heart disease, while the use of tamoxifen increases the risk of thromboembolic events.

BREAST CANCER RESEARCH AND TREATMENT (2021)

添加到收藏夹

Review Obstetrics & Gynecology

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare

Volkmar Mueller, Peter A. Fasching, Naiba Nabieva, Tanja N. Fehm, Marc Thill, Marcus Schmidt, Thorsten Kuehn, Maggie Banys-Paluchowski, Erik Belleville, Ingolf Juhasz-Boess, Michael Untch, Hans-Christian Kolberg, Nadia Harbeck, Bahriye Aktas, Elmar Stickeler, Julia Kreuzeder, Andreas D. Hartkopf, Wolfgang Janni, Nina Ditsch

Summary: For breast cancer patients with existing ovarian function, there are special considerations for adjuvant endocrine therapy. However, there is currently no clear definition of intermediate or high risk patients in national and international guidelines, leading to individualized therapy decisions.

GEBURTSHILFE UND FRAUENHEILKUNDE (2023)

添加到收藏夹

Review Obstetrics & Gynecology

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare

Volkmar Mueller, Peter A. Fasching, Naiba Nabieva, Tanja N. Fehm, Marc Thill, Marcus Schmidt, Thorsten Kuehn, Maggie Banys-Paluchowski, Erik Belleville, Ingolf Juhasz-Boess, Michael Untch, Hans-Christian Kolberg, Nadia Harbeck, Bahriye Aktas, Elmar Stickeler, Julia Kreuzeder, Andreas D. Hartkopf, Wolfgang Janni, Nina Ditsch

Summary: In premenopausal patients with hormone receptor-positive, HER2-negative breast cancer, adjuvant endocrine therapy presents special considerations in those with ovarian function. Treatment options such as tamoxifen with or without a GnRH analog, and aromatase inhibitors with a GnRH analog are available. Previous chemotherapy affects ovarian function. Aromatase inhibitors (+ GnRH analogs) and GnRH analogs in combination with tamoxifen are indicated for patients at increased risk of recurrence. However, current guidelines lack clear definitions for intermediate or high risk, leading to individualized therapy decisions. Variability exists in the use of aromatase inhibitors + GnRH analogs at national and international levels. This review provides a summary of completed studies, ongoing multigene testing studies, discusses current rationale, and looks towards future questions.

GEBURTSHILFE UND FRAUENHEILKUNDE (2023)

添加到收藏夹

Article Oncology

A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)

Mario Campone, Thomas Bachelot, Isabelle Treilleux, Barbara Pistilli, Julia Salleron, Valerie Seegers, Monica Arnedos, Delphine Loussouarn, Qing Wang, Laurence Vanlemmens, Marta Jimenez, Maria Rios, Veronique Dieras, Agnes Leroux, Gilles Paintaud, Keyvan Rezai, Fabrice Andre, Maeva Lion, Jean-Louis Merlin

Summary: Adding everolimus to preoperative trastuzumab did not improve efficacy but induced MAPK signaling in HER2-positive early operable breast cancer patients. Combination therapy should be considered to maximize the effectiveness of trastuzumab in this setting.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients

Niklas Gremke, Sebastian Griewing, Saket Chaudhari, Swati Upadhyaya, Ivan Nikolov, Karel Kostev, Matthias Kalder

Summary: The aim of this study was to analyze the persistence of women on tamoxifen (TAM) and aromatase inhibitors (AIs) in Germany, and to investigate possible determinants of non-persistence. The study found that the persistence rates were low for both TAM and AI treatment, and factors such as physician specialty, younger age, and type of endocrine therapy were associated with an increased risk for non-persistence.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Background Parenchymal Enhancement at Postoperative Surveillance Breast MRI: Association with Future Second Breast Cancer Risk

Su Hyun Lee, Myoung-jin Jang, Heera Yoen, Youkyoung Lee, Yeon Soo Kim, Ah Reum Park, Su Min Ha, Soo-Yeon Kim, Jung Min Chang, Nariya Cho, Woo Kyung Moon

Summary: Background parenchymal enhancement (BPE) at surveillance breast MRI is associated with future second breast cancer risk in women with a personal history of breast cancer.

RADIOLOGY (2023)

添加到收藏夹

Article Oncology

Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR)

Olivier Tredan, Magali Provansal, Cyril Abdeddaim, Audrey Lardy-Cleaud, Anne-Claire Hardy-Bessard, Elsa Kalbacher, Anne Floquet, Laurence Venat-Bouvet, Alain Lortholary, Oana Pop, Jean-Sebastien Frenel, Mathilde Cancel, Remy Largillier, Christophe Louvet, Benoit You, Alain Zannetti, Amelie Anota, Isabelle Treilleux, Daniel Pissaloux, Aurelie Houlier, Aude-Marie Savoye, Marie-Ange Mouret-Reynier, Jerome Meunier, Charles-Briac Levache, Fabien Brocard, Isabelle Ray-Coquard

Summary: This study evaluated the efficacy and safety of regorafenib versus tamoxifen in platinum-sensitive ovarian cancer biological recurrence. The results showed regorafenib had a less favorable safety profile compared to tamoxifen, but no superior efficacy in this population of patients.

GYNECOLOGIC ONCOLOGY (2022)

添加到收藏夹

Article Obstetrics & Gynecology

The Endocrine Treatment Landscape for Patients with HR+ HER2-Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy - A Real-World Analysis

Naiba Nabieva, Falk Altmann, Klaus Apel, Dirk-Toralf Baerens, Michaela Beha, Antje Belau, Steffi Busch, Dagmar Guth, Georg Heinrich, Janine Kreiss-Sender, Susanne Markmann, Andreas Olbermann, Guelten Oskay-Oezcelik, Beatrix Schuback, Dieter Steinfeld-Birg, Claudia Quiering, Ferenc Kiss, Julia Kreuzeder, Paolo Nuti, Joerg Schilling

Summary: This retrospective analysis examined the endocrine therapy received by German patients with HR+ HER2- early breast cancer before the availability of CDK4/6 inhibitors. The results showed that over half of the patients did not receive chemotherapy, and only one third of premenopausal patients received GnRH in addition to standard endocrine therapy. Further studies are needed to assess how the introduction of CDK4/6 inhibitors may have changed the endocrine therapy landscape in Germany.

GEBURTSHILFE UND FRAUENHEILKUNDE (2023)

添加到收藏夹

Article Oncology

Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study

Heather Greenlee, Carlos Iribarren, Jamal S. Rana, Richard Cheng, Mai Nguyen-Huynh, Eileen Rillamas-Sun, Zaixing Shi, Cecile A. Laurent, Valerie S. Lee, Janise M. Roh, Margarita Santiago-Torres, Hanjie Shen, Dawn L. Hershman, Lawrence H. Kushi, Romain Neugebauer, Marilyn L. Kwan

Summary: This study found that women with breast cancer had significantly increased incidence of cardiovascular disease events, CVD-related mortality, and all-cause mortality compared with women without breast cancer, with risks varying according to the history of cancer treatment received. Studies are needed to determine optimal care for women who have received breast cancer treatment to improve cardiovascular outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Carpal tunnel syndrome and tenosynovitis in women with breast cancer associated with hormone therapy A multi-institutional analysis using a clinical data warehouse

Dong Jae Shin, Kyung Eun Nam, Dae Heon Song, Sun Im, Sun Jae Won, Yeo Hyung Kim, Seong Hoon Lim, Jong In Lee

Summary: This study evaluates the characteristics, treatments, and incidence rates of carpal tunnel syndrome (CTS) and tenosynovitis in women with breast cancer, according to the hormone therapy used. The research found that aromatase inhibitor (AI) users have a higher incidence of CTS and tenosynovitis compared to other hormone therapy groups. More than half of CTS and tenosynovitis cases occurred within 12 months after hormone commencement.

MEDICINE (2022)

添加到收藏夹

Article Nutrition & Dietetics

Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions

Maura Harrigan, Courtney McGowan, Annette Hood, Leah M. Ferrucci, ThaiHien Nguyen, Brenda Cartmel, Fang-Yong Li, Melinda L. Irwin, Tara Sanft

Summary: Dietary supplement use is common among breast cancer survivors, with a high prevalence of potential adverse interactions between prescribed endocrine therapy and dietary supplements.

NUTRIENTS (2021)

添加到收藏夹

Article Oncology

Identification of factors that influence the decision to take chemoprevention in patients with a significant family history of breast cancer: results from a patient questionnaire survey

Stacey Jones, Brian Hogan, Kirtida Patel, Shiwei Ooi, Philip Turton, Rajgopal Achuthan, Baek Kim

Summary: The study found that the uptake of chemoprevention is low in breast cancer patients with high family history risk. The main motivating factors for accepting chemoprevention were breast cancer prevention, belief in its effectiveness, and personal perception of breast cancer risk. On the other hand, the main barriers for refusal included concerns about side effects and lack of information.

BREAST CANCER RESEARCH AND TREATMENT (2021)

添加到收藏夹

Article Oncology

Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study

Xia-Bo Shen, Guang-Liang Li, Ya-Bing Zheng, Zhan-Hong Chen, Wen-Ming Cao, Xiao-Jia Wang, Xi-Ying Shao

Summary: For Chinese patients with hormone-receptor-positive breast cancer, EVE combined with endocrine therapy is an effective treatment option. Liver metastasis and brain metastasis are independent risk factors for successful EVE combined with endocrine therapy.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement-A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO

Leila Bengrine, Naoual Bakrin, Frederique Rousseau, Vincent Lavoue, Claire Falandry

Summary: This position paper proposes a multidisciplinary care planning for older patients with ovarian cancer, highlighting the importance of adapting care plans to geriatric parameters and evaluating the impact of geriatric interventions on patient outcomes through further studies.

CANCERS (2022)

添加到收藏夹

Review Obstetrics & Gynecology

Combining prehabilitation with enhanced recovery programs in gynecological surgery

Claire Falandry, Raffaele Fauvet, Pascal Alfonsi, Arthur Foulon, Celia Texier, Nicolas Bourdel, Therese Simonet, Henri Azais, Eric Lambaudie

Summary: Prehabilitation is a multimodal approach to preoperative care that aims to reduce stress and apprehension, promote general well-being, and optimize the patient's health before surgery. It includes physical exercise, dietary interventions, smoking and alcohol cessation, and psychological care.

JOURNAL OF GYNECOLOGY OBSTETRICS AND HUMAN REPRODUCTION (2022)

添加到收藏夹

Meeting Abstract Oncology

Optimizing the management of PARP inhibitors in clinical practice: Results of a DELPHI French consensus

F. Selle, F. Scotte, J-J. Boffa, G. Etienne, A. Angelergues, P. Augereau, D. Berton-Rigaud, P. Dielenseger, M. Fabbro, C. Falandry, P. Follana, L. Gladieff, F. Joly Lobbedez, J. E. Kurtz, C. Matta, M. A. Mouret Reynier, A. Schmitt, C. Marjollet, A. Floquet

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Practical management of PARP inhibitors: A French DELPHI consensus

Frederic Selle, Jean-Jacques Boffa, Gabriel Etienne, Antoine Angelergues, Paule Augereau, Dominique Berton, Pascale Dielenseger, Michel Fabbro, Claire Falandry, Philippe Follana, Laurence Gladieff, Florence Joly, Jean-Emmanuel Kurtz, Carla Matta, Marie-Ange Mouret-Reynier, Antonin Schmitt, Florian Scotte, Coralie Marjollet, Anne Floquet

Summary: This study aims to establish guidelines for the management of PARP inhibitors based on the needs of healthcare professionals and patients. Using the Delphi method, multiple statements were drafted and anonymously voted on by clinicians. The study provides 52 statements on the treatment of PARP inhibitors, with consensus among the voters.

BULLETIN DU CANCER (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial

Thomas Aparicio, Olivier Bouche, Pierre-Luc Etienne, Emilie Barbier, Laurent Mineur, Romain Desgrippes, Veronique Guerin-Meyer, Faycal Hocine, Jean Martin, Valerie Le Brun-Ly, Jacques Cretin, Jerome Desrame, Yves Rinaldi, Laurent Cany, Claire Falandry, Leila Bengrine Lefevre, Miguelle Marous, Eric Terrebonne, Laurent Mosser, Justine Turpin, Anthony Turpin, Lucille Bauguion, Cynthia Reichling, Marc Van den Eynde, Elisabeth Carola, Sandrine Hiret

Summary: In the preliminary tolerance analysis of the ADAGE-PRODIGE 34 trial, it was found that in patients over 70 years old, the group of patients treated with oxaliplatin and fluoropyrimidine had more grade 3-5 toxicities compared to the group treated with fluoropyrimidine alone in the fit patients.

DIGESTIVE AND LIVER DISEASE (2023)

添加到收藏夹

Review Oncology

Advances in the management of peritoneal malignancies

Vahan Kepenekian, Aditi Bhatt, Julien Peron, Mohammad Alyami, Nazim Benzerdjebz, Naoual Bakrin, Claire Falandry, Guillaume Passot, Pascal Roussetz, Olivier Glehen

Summary: This article comprehensively describes the improvements in understanding and management of peritoneal surface malignancies, including biology, assessment and classification, surgical management, systemic treatment, and pre-emptive management. The authors also outline future research directions in this field.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Correction Oncology

New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology (Aug, 10.1007/s11912-022-01324-x, 2022)

Lodovico Balducci, Claire Falandry, Alan List

CURRENT ONCOLOGY REPORTS (2022)

添加到收藏夹

Review Oncology

New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology

Lodovico Balducci, Claire Falandry, Alan List

Summary: Trilaciclib and ALRN-6924 can prevent chemotherapy-induced toxicity by inducing cell cycle arrest, thus reducing the adverse effects of cancer treatment and improving outcomes in older patients.

CURRENT ONCOLOGY REPORTS (2022)

添加到收藏夹

Review Geriatrics & Gerontology

A Proactive Approach to Prevent Hematopoietic Exhaustion During Cancer Chemotherapy in Older Patients: Temporary Cell-Cycle Arrest

Lodovico Balducci, Claire Falandry, Alan List

Summary: Age is associated with the decline of multiple organ systems. Two molecules, trilaciclib and ALRN-6924, have emerged as novel strategies to prevent chemotherapy toxicity by inducing cell-cycle arrest. Trilaciclib inhibits CDK 4/6 to cause cell-cycle arrest, while ALRN-6924 activates p53. These drugs have shown promising results in preventing hematological toxicities in patients with small cell lung cancer and may also preserve the stem cell reserve of other tissues with high turnover.

DRUGS & AGING (2023)

添加到收藏夹

Review Geriatrics & Gerontology

Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database

Gabriel Antherieu, Mael Heiblig, Gilles Freyer, Herve Ghesquieres, Claire Falandry

Summary: This study found a high incidence of lymphopenia in adult patients treated with PARPi, especially in older patients, through a retrospective cohort study and scoping review analysis. Future work is needed to improve patient follow-up and discuss prophylactic strategies.

DRUGS & AGING (2023)

添加到收藏夹

Review Geriatrics & Gerontology

Cell cycle arrest: A breakthrough in the supportive care of older cancer patients

Claire Falandry, Alan List, Lodovico Balducci

Summary: Older patients are at a higher risk of complications from cancer chemotherapy. Two new drugs, Trilaciclib and ALRN-6924, have been found to temporarily arrest the cell cycle of normal cells, making them resistant to chemotherapy toxicity. This proactive approach is particularly beneficial for older patients.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2023)

添加到收藏夹

Review Oncology

Ovarian cancer in the older patient: where are we now? What to do next?

Frederique Rousseau, Florence Ranchon, Christophe Bardin, Naoual Bakrin, Vincent Lavoue, Leila Bengrine-Lefevre, Claire Falandry

Summary: In recent years, there have been major advances in individualized care for epithelial ovarian cancer, but the oldest populations have not benefited. Therefore, specific considerations should be taken into account when making decisions about surgery, chemotherapy, and maintenance treatments for older patients.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Screening for hypertension-mediated organ damage and aetiology: still of value after 65 years of age?

D. Thiolliere, C. Debouzy, B. Harbaoui, C. Moulayat, C. Falandry, P. Lantelme, P. Courand

Summary: The prevalence and type of hypertension-mediated organ damage (HMOD) and secondary forms differ between older and younger hypertensive patients. In patients aged 65 and above, carotid femoral pulse wave velocity > 10 m/s is the most common HMOD, while echocardiographic left ventricular hypertrophy is the most common in younger patients.

JOURNAL OF GERIATRIC CARDIOLOGY (2022)

添加到收藏夹

Article Anesthesiology

Prognosis of Old Intensive Care COVID-19 Patients at a Glance: The Senior COVID Study

Charles-Herve Vacheron, Laurent Bitker, Fabrice Thiolliere, Fabien Subtil, Paul Abraham, Vincent Collange, Baptiste Balanca, Max Haine, Celine Guichon, Christophe Leroy, Marie Simon, Amelie Malapert, Melanie Roche, Jean-Baptiste Pialat, Laurent Jallades, Alain Lepape, Arnaud Friggeri, Claire Falandry

Summary: This study aimed to explore the ethical issue of admitting elderly patients with coronavirus disease 19 to the intensive care unit, and developed a model to predict the 30-day mortality rate. The results showed that age, autonomy, dementia, and severity at admission were important predictive factors.

TURKISH JOURNAL OF ANAESTHESIOLOGY AND REANIMATION (2022)

添加到收藏夹

Article Geriatrics & Gerontology

Senior-COVID-Rea Cohort Study: A Geriatric Prediction Model of 30-day Mortality in Patients Aged over 60 Years in ICU for Severe COVID-19

Claire Falandry, Laurent Bitker, Paul Abraham, Fabien Subtil, Vincent Collange, Baptiste Balanca, Max Haine, Celine Guichon, Christophe Leroy, Marie Simon, Amelie Malapert, Jean-Baptiste Pialat, Laurent Jallades, Alain Lepape, Arnaud Friggeri, Fabrice Thiolliere

Summary: The COVID-19 pandemic has caused tensions in healthcare systems and ethical dilemmas. This study found that age and IADL8 are independent prognostic factors for 30-day mortality in patients aged 60 years and above.

AGING AND DISEASE (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.